Impactos dos tratamentos para melasma na qualidade de vida e autoestima feminina: uma revisão integrativa
DOI:
https://doi.org/10.18310/2446-4813.2026v12n2.4760Palavras-chave:
Melasma, Qualidade de Vida, AutoestimaResumo
Objetivos: Analisar os impactos dos tratamentos para melasma na qualidade de vida e na autoestima de mulheres, condição caracterizada como hiperpigmentação cutânea crônica, multifatorial e recorrente, para a qual ainda não existe protocolo terapêutico padrão consolidado. Fonte de Dados: Trata-se de uma revisão integrativa da literatura, conduzida entre novembro e dezembro de 2024, com busca nas bases de dados PubMed, Scopus e Web of Science. Foram elegíveis estudos observacionais e intervencionais publicados entre 2019 e 2024, em inglês e/ou português, realizados exclusivamente com mulheres com melasma e que empregaram instrumentos validados de avaliação da qualidade de vida. A seleção e a extração dos dados foram conduzidas por dois pesquisadores de forma independente, com divergências resolvidas por consenso. De 436 estudos identificados, 19 atenderam aos critérios de inclusão. Resumo das Conclusões: Os 19 estudos incluídos apresentaram, em sua maioria, delineamento intervencional. Identificou-se ampla diversidade terapêutica, com destaque para a hidroquinona, utilizada isoladamente ou em combinação. A qualidade de vida foi avaliada predominantemente pelo instrumento MELASQoL. Os achados indicaram que a redução das manchas associa-se à melhora significativa da qualidade de vida e da autoestima das pacientes, enquanto estudos observacionais confirmaram o impacto negativo do melasma nesses desfechos. Limitações como amostras reduzidas e ausência de seguimento a longo prazo restringem a generalização dos resultados, reforçando a necessidade de investigações mais robustas.
Referências
1. Borges MC. Melasma: tratamento e suas implicações estéticas. Health Hum. 2021;3(1):8-19. doi:10.6008/CBPC2674-6506.2021.001.0002.
2. Espósito ACC, Cassiano DP, Da Silva CN, Lima PB, Dias JAF, Hassun K, et al. Update on Melasma—Part I: Pathogenesis. Dermatol Ther. 2022;12(9):1967-88. doi:10.1007/s13555-022-00779-x.
3. Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. julho de 2018;31(4):461-5. doi:10.1111/pcmr.12684.
4. Desai S, Alexis A. Melasma: epidemiology and pathogenesis update. Am J Clin Dermatol. 2024;25(1):45-60.
5. Demir FT, Altun E. Comparison of platelet-rich plasma efficacy with and without photoactivation in melasma: a randomized double-blind study. J Cosmet Dermatol. 2024;23(12):3911-7. doi:10.1111/jocd.16540.
6. Kagha K, Fabi S, Goldman MP. Melasma’s Impact on Quality of Life. J Drugs Dermatol JDD. 2020;19(2):184-7. doi:10.36849/JDD.2020.4663.
7. Dabas G, Vinay K, Parsad D, Kumar A, Kumaran MS. Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. J Eur Acad Dermatol Venereol JEADV. 2020;34(2):392–9. doi:10.1111/jdv.15987.
8. Chen W, Wan Y, Sun Y, Gao C, Li J. Prevalence of depression in melasma: a systematic review and meta-analysis. Front Psychiatry. 2023;14:1276906. doi:10.3389/fpsyt.2023.1276906.
9. Rajanala S, Maymone MBDC, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J. 2019;25(10). doi:10.5070/D32510045810.
10. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date comprehensive review. Dermatol Ther. 2017;7(3):305–18. doi:10.1007/s13555-017-0194-1.
11. Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australas J Dermatol. 2015;56(3):151–63. doi:10.1111/ajd.12290.
12. Sepaskhah M, Karimi F, Bagheri Z, Kasraee B. Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma. J Cosmet Dermatol. 2022;21(7):2871–8. doi:10.1111/jocd.15048.
13. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi:10.1186/s13643-016-0384-4.
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. doi:10.1136/bmj.n71
15. De Andrade ACDV, Coqueiros RDS, Pithon MM, Leite MF. Peeling with retinoic acid in microemulsion fro treatment of melasma: a double-blind randomized controlled clinical study. J Cosmet Dermatol. 2024;23(2):479–85. doi:10.1111/jocd.15959.
16. Crocco EI, Torloni L, Fernandes PB, De Campos MEBB, Gonzaga M, Silva FC, et al. Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety. J Cosmet Dermatol. 2024;23(5):1703–12. doi:10.1111/jocd.16183.
17. Lima PB, Dias JAF, Esposito ACC, Miot LDB, Miot HA. French maritime pine bark extract (pycnogenol)
in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. fevereiro de 2021;35(2):502–8. doi:10.1111/jdv.16896.
18. Lima PB, Dias JAF, Cassiano DP, Esposito ACC, Miot LDB, Bagatin E, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol. 2021;35(9):1881–7. doi:10.1111/jdv.17344.
19. Manzoni APD, Lorenzini FK, Lipnharski C, Weber MB, Nogueira JF, Rizzati K. Estudo comparativo, split face entre luz intensa pulsada com modo pulse-in-pulse. Surg Cosmet Dermatol. 2018;10(3). doi:10.5935/scd1984-8773.20191131420.
20. Onder S, Demircan Y, Aksaç S, Ozturk M, Etgü F. Examining the effects of melasma on women’s quality of life: A study from eastern black sea region of Turkey. Turk J Dermatol. 2021;15(3):55. doi:10.4103/tjd.tjd_33_21.
21. Türkmen H, Yörük S. Risk factors of striae gravidarum and chloasma melasma and their effects on quality of life. J Cosmet Dermatol. 2023;22(2):603–12. doi:10.1111/jocd.14783.
22. Wubulí G, Zengin N. The Relationship between socio-demographic characteristics body image and quality of life with physiological skin changes in pregnancy. J Midwifery Reprod Health. 2023;11(3). doi:10.22038/jmrh.2023.66553.1941.
23. Ahramiyanpour N, Mahmoudi Z, Nezhad NZ, Khazaeli P, Amiri R, Kasraee B. Topical isoniazid as a novel treatment for melasma: a randomized, double-blind, vehicle-controlled clinical trial. J Cosmet Dermatol. 2024;23(8):2636–43. doi:10.1111/jocd.16320.
24. Bakhtyari L, Shirbeigi L, Tabarrai M, Rahimi R, Ayatollahi A. Efficacy of a polyherbal syrup containing lemon balm, damask rose, and fennel to treat melasma: a randomized, triple - blind, controlled clinical trial. Jundishapur J Nat Pharm Prod. 2023;18(3). doi:10.5812/jjnpp-138392.
25. El-Husseiny R, Rakha N, Sallam M. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treatim melasma: a split-face comparative clinical, histopathological, and antera 3D camera study. Dermatol Ther. 2020;33(6). doi:10.1111/dth.14240.
26. Huang P, Acevedo SF, Cheng T, Mehta RC, Makino ET. A randomized, controlled, split-face, double-blind comparison of a multimodality pigment-correcting serum containing lotus sprout extract versus hydroquinone for moderate to severe facial hyperpigmentation, including melasma, in a diverse population. JAAD Int. 2024;15:206–19. doi:10.1016/j.jdin.2024.02.017.
27. Kaikati J, El Bcherawi N, Khater JA, Dib SM, Kechichian E, Helou J. Combination topical tranexamic acid and vitamin C for the treatment of refractory melasma. J Clin Aesthetic Dermatol. 2023;16(7):63–5.
28. Nguyen J, Remyn L, Cung IY, Honigman A, Gourani-Tehrani S, Wutami I, et al. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial. Australas J Dermatol. 2021;62(1). doi: 10.111/ajd.13432.
29. Qayyum M, Siddiqui S, Awais M, Ilyas M, Shahzad A, Azfar NA. Correlation between quality of life and clinical severity of melasma in Pakistani women. J Pak Assoc Dermatol. 2022;32(4):683–9. doi:10.66344/jpad.32.4.2022.1999.
30. Rao SK, T. S. R, Ashraf A. Efficacy of intralesional tranexamic acid in melasma: Assessment with Melasma Area Severity Index and Dermatology Quality of Life Index. Turkderm-Turk Arch Dermatol Venereol. 2022;56(2):58–63. doi:10.4274/turkderm.galenos.2022.42709.
31. Roggenkamp D, Sammain A, Furstenau M, Kausch M, Passeron T, Kolbe L. Thiamidol in moderate-to-severe melasma: 24-week, randomized, double-blind, vehicle-controlled clinical study with subsequent regression phase. J Dermatol. 2021;48(12):1871–6. doi:10.1111/1346-8138.16080.
32. Zhu Y, Xu J, Song X, Xiang W. Comparative study of melasma in patients before and after treatment based on lipomics. Lipids Health Dis. 2024;23(1):138. doi:10.1186/s12944-024-02130-z.
33. Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, Wehrlen Pugliese S, et al. Efficacy and safety of a novel triple combination cream compared to Kingman's trio for melasma: a 24-week double-blind prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2601–7. doi:10.1111/jdv.19455.
34. Altiokka Ì, Uner M. Safety in Cosmetics and Cosmetovigilance, Current Regulations in Turkiye. Turk J Pharm Sci. 2022;19(5):610–7. doi:10.4274/tjps.galenos.2021.40697.
35. Juhász ML, Levin MK, Marmur ES. The use of natural ingredients in innovative Korean cosmeceuticals. J Cosmet Dermatol. 2018;17(3):305–12. doi:10.1111/jocd.12492.
36. Nguyen JK, Masub N, Jagdeo J. Bioactive ingredients in Korean cosmeceuticals: Trends and research evidence. J Cosmet Dermatol. 2020;19(7):1555–69. doi:10.1111/jocd.13344.
37. Morgado-Carrasco D, Piquero- Casals J, Granger C, Trullàs C, Passeron T. Melasma: The need for tailored photoprotection to improve clinical outcomes. Photodermatol Photoimmunol Photomed. 2022;38(6):515–21. doi:10.1111/phpp.12783.
38. Cassiano DP, Espósito ACC, Da Silva CN, Lima PB, Dias JAF, Hassun K, et al. Update on Melasma—Part II: Treatment. Dermatol Ther. 2022;12(9):1989–2012. doi:10.1007/s13555-022-00780-4.
39. Sarkar R, Handog EB, Das A, Bansal A, Macarayo MaJ, Keshavmurthy V, et al. Topical and Systemic Therapies in Melasma: A Systematic Review. Indian Dermatol Online J. 2023;14(6):769–81. doi:10.4103/idoj.idoj_490_22.
40. Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023;22(4):1197–206. doi:10.1111/jocd.15589.
41. Mahjoub TT, Milibary HH. Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: a review. J Cosmet Dermatol. 2023;22(4):1157–62. doi:10.1111/jocd.15561.
42. Mpofana N, Chibi B, Gqaleni N, Hussein A, Finlayson AJ, Kgarosi K, et al. Melasma in people with darker skin types: a scoping review protocol on prevalence, treatment options for melasma and impact on quality of life. Syst Rev. 2023;12(1):139. doi:10.1186/s13643-023-02300-7.
43. Mpofana N, Paulse M, Gqaleni N, Makgobole MU, Pillay P, Hussein A, et al. The Effect of melasma on the quality of life in people with darker skin types living in Durban, South Africa. Int J Environ Res Public Health. 2023;20(22):7068. doi:10.3390/ijerph20227068.
44. Zhu Y, Zeng X, Ying J, Cai Y, Qiu Y, Xiang W. Evaluating the quality of life among melasma patients using the MELASQoL scale: a systematic review and meta-analysis. Kaliyadan F, organizador. PLOS ONE. 2022;17(1):e0262833. doi:10.1371/journal.pone.0262833.
45. Platsidaki E, Efstathiou V, Markantoni V, Kouris A, Kontochristopoulos G, Nikolaidou E, et al. Self-esteem, depression, anxiety and quality of life in patients with melasma living in a sunny mediterranean area: results from a prospective cross-sectional study. Dermatol Ther. 2023;13(5):1127–36. doi:10.1007/s13555-023-00915-1.
46. Motta BS, Teixeira EDR, Rosa VA, Aguiar EL. Impacto psicológico das doenças dermatológicas: repercussões psicossociais. J Arch Health. 2025;6(4):e2832. doi:10.46919/archv6n4espec-15761.
47. Dalgard FJ, Svensson Å, Halvorsen JA, Gieler U, Schut C, Tomas-Aragones L, et al. Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries. J Invest Dermatol. 2020;140(3):568–73. doi:10.1016/j.jid.2019.05.034.
48. Ribeiro LR, Costa GD, Borges DFP, Letrari LXDM, Alcântara DSD, Buges NM, et al. Da mente à pele: estresse, ansiedade e estratégias para o manejo das psicodermatoses em adultos. Obs Econ Latinoam. 2025;23(12):e12613. doi:10.55905/oelv23n12-081.
49. Chen W, Wan Y, Sun Y, Gao C, Li J. Prevalence of depression in melasma: a systematic review and meta-analysis. Front Psychiatry. 2024;14:1276906. doi:10.3389/fpsyt.2023.1276906.
50. Gopalan K, Gunasegaran I, Anjum AA, Ganga vellaisamy S, Manickam N. A clinico-epidemiological study and quality of life assessment in melasma at a tertiary care centre in South India. J Pak Assoc Dermatol. 2024;34(4):985–95. doi:10.66344/jpad.34.4.2024.2771.
51. Jusuf NK, Putra IB, Mahdalena M. Is There a Correlation between Severity of Melasma and Quality of Life? Open Access Maced J Med Sci. 2019;7(16):2615–8. doi:10.3889/oamjms.2019.407.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2026 Reijane Alves Matos, Sheila Feitosa Ramos, André Leandro Silva
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os direitos autorais para artigos publicados neste periódico são do autor, com os direitos de publicação para o periódico. Este periódico é de acesso público, os artigos são de uso gratuito, com atribuições próprias, desde que citada a fonte (por favor, veja a Licença Creative Commons no link a seguir https://creativecommons.org/licenses/by/4.0/deed.pt_BR).
